Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NTP

This article was originally published in The Rose Sheet

Executive Summary

Di(2-ethylhexyl) phthalate monograph will be released in October by National Toxicology Program's Center for the Evaluation of Risks to Human Reproduction, agency reports during Board of Scientific Counselors Meeting Sept. 10-11 in Research Triangle Park, N.C. NTP released a monograph on di-n-butyl phthalate in March (1"The Rose Sheet" March 24, 2003, p. 6). Agency also unveiled its draft vision for the toxicology program, which advocates shifting basis for decision-making to rely on faster, mechanism-based assays rather than empirical tests. NTP anticipates developing more specific draft principles, roadmap of goals to be accomplished under new strategy by July 2004...

You may also be interested in...



Di-N-Butyl Phthalate Monograph Released By NTP

The National Toxicology Program has "some concern" di-n-butyl phthalate causes adverse effects to human development, particularly development of the reproductive system, according to a monograph released by NTP's Center for the Evaluation of Risks to Human Reproduction in a 1March 18 Federal Register notice

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

UsernamePublicRestriction

Register

RS011518

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel